Stepan reports Q4 adjusted EPS 12c, consensus 33c

Reports Q4 revenue $525.609M, consensus $520.97M. “While we are disappointed with our overall financial performance in 2024, we advanced our strategic investments and took necessary steps to return the Company to profitable growth. I am proud of the resilience, hard work and dedication of the entire organization. Full year Adjusted EBITDA grew 4% versus prior year despite several one-time events that negatively impacted earnings and the pre-operating expenses in our new Pasadena, site,” said Luis E. Rojo, President and Chief Executive Officer. “Surfactants and Specialty Products delivered strong double-digit Adjusted EBITDA growth, partially offset by demand weakness in Polymers. Overall, global sales volume grew 1%, driven by 2.5% growth in our Surfactant business. We are encouraged by the Surfactant growth within several of our key strategic end markets. We delivered $39 million of free cash flow, which was in line with our expectations, and we increased our dividend for the 57th consecutive year. We completed the majority of our new Pasadena, Texas site which is critical to growing our alkoxylation business. Our strong foundation, combined with the cost reductions and strategic investments we have made, position us well to deliver future growth.”